title: [The effect of polyamidoamine (PAMAM) dendrimers on the solubility and pharmacokinetics of breviscapine].
abstract: To study the solubilization of breviscapine with polyamidoamine (PAMAM) dendrimers and probe the solubilizing mechanism and investigate the influence of PAMAM dendrimers on the pharmacokinetics of breviscapine, the solubilization of breviscapine by PAMAM dendrimers of generations G1, G1.5, G2 and G2.5 with different concentrations were determined and compared in different pH conditions. Twelve rats randomized into 2 groups were separately orally administered breviscapine and breviscapine combining with PAMAM. Drug in plasma was extracted and determined with HPLC. In pH condition lower than 7.0, the solubilization of breviscapine by PAMAM dendrimers enhanced as the generation and concentration of PAMAM dendrimers as well as the pH increased. Its solubilizing mechanism involves an electrostatic interaction between the carboxyl group of breviscapine and the primary amines and tertiary amines of PAMAM dendrimers. The pharmacokinetics parameters Cmax and AUC0-8 h of breviscapine were (119.65 +/- 9.36) ng x mL(-1) and (370.09 +/- 63.08) ng x h x mL(-1). For breviscapine combined with PAMAM dendrimers, the Cmax and AUC0-8 h were (518.17 +/- 17.07) ng x mL(-1) and (1,219.47 +/- 201.87) ng x h x mL(-1), respectively. There were significant differences of AUC0-8 h between breviscapine and breviscapine combined with PAMAM dendrimers (P < 0.01). PAMAM dendrimers can greatly increase the solubility of breviscapine in water and can improve the oral bioavailability of breviscapine significantly.
authors.affiliation: Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
authors.forename: Jun-Jun
authors.initials: JJ
authors.lastname: Lu
authors.forename: Zheng-Hong
authors.initials: ZH
authors.lastname: Wu
authors.forename: Qi-Neng
authors.initials: QN
authors.lastname: Ping
mesh_terms: D000818:Animals; D019540:Area Under Curve; D001672:Biocompatible Materials; D001682:Biological Availability; D050091:Dendrimers / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D004337:Drug Carriers; D049919:Erigeron / Q000737:chemistry; D005419:Flavonoids / Q000737:chemistry* / Q000302:isolation & purification / Q000493:pharmacokinetics*; D006863:Hydrogen-Ion Concentration; D008297:Male; D015394:Molecular Structure; D010946:Plants, Medicinal / Q000737:chemistry; D011073:Polyamines / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility / Q000187:drug effects
chemical_list: D001672:Biocompatible Materials; D050091:Dendrimers; D004337:Drug Carriers; D005419:Flavonoids; C104700:PAMAM Starburst; D011073:Polyamines; C061097:breviscapine